侯旭奔,副教授,博士生导师。山东大学青年学者未来计划,山东省高等学校青年创新团队带头人,国家一流课程《药物设计学》团队成员。主要从事靶向蛋白翻译后修饰的药物设计、合成与化学生物学研究。近年来以第一作者/通讯作者在J. Med. Chem., Cell Chem. Biol., Acta Pharm. Sin. B, Eur. J. Med. Chem., J. Biol. Chem., J. Chem. Inf. Model.等杂志发表SCI论文40余篇,主持国家自然科学基金面上项目、国家自然科学基金青年基金、国家卫生健康委课题,山东省青年基金等科研项目。
学习及工作经历
Ø 2007.9- 2011.6山东大学药学院,药学,学士
Ø 2011.8-2012.8 共青团中央山东大学研究生支教团(西部计划)
Ø 2012.9- 2017.6 山东大学药学院,药物化学,硕博连读 (导师:方浩教授)
Ø 2015.10-2017.4 New York University,公派联合培养(导师:Prof. Yingkai Zhang)
Ø 2017.7- 2018.8 New York University,博士后(导师:Prof. Yingkai Zhang)
Ø 2018.12-2022.9山东大学药学院,副研究员
Ø 2022.9-至今 山东大学药学院,副教授
研究方向
Ø 靶向蛋白翻译后修饰的药物设计、合成与化学生物学研究。
Ø 针对新靶标的高通量虚拟筛选与活性先导化合物发现。
Ø 复杂生物大分子体系的计算模拟与化学干预。
主持科研项目
1. 国家自然科学基金面上项目(22377068),2024-2027,在研
2. 国家自然科学基金青年科学基金项目(82003590),结题
3. 山东省自然科学基金青年科学基金项目(ZR2020QH342),结题
4. 国家卫生与健康委员会课题(GWJJ2022100301-5),2020-2025,在研
5. 山东大学青年学者未来计划(2019-2024),在研
6. 山东大学中澳健康科学研究中心合作研究项目,结题
7. 山东大学-卡罗林斯卡医学院国际合作项目,结题
代表性论文
1. Chang Y, Guo H, Li X, Zong L, Wei J, Li Z, Luo C, Yang X, Fang H, Kong X*, Hou X*. Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity. J Med Chem. 2024, doi: 10.1021/acs.jmedchem.4c01310.
2. Liu M, Gao S, Wang Y, Yang X, Fang H*, Hou X*. Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death. J Med Chem. 2024, 67(17):15098-15117.
3. Liu M, Gao S, Liang T, Qiu X, Yang X, Fang H*, Hou X*. Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity. J. Med. Chem. 2022, 65(18):12200-12218.
4. Chen C, Li X, Zhao H, Liu M, Du J, Zhang J, Yang X, Hou X*, Fang H*. Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity. J. Med. Chem. 2022, 65(4):3667-3683.
5. Jin X#, Hou X#, Wang X, Zhang M, Chen J, Song M, Zhang J, Zheng H, Chang W, Lou H. Characterization of an allosteric inhibitor of fungal-specific C-24 sterol methyltransferase to treat Candida albicans infections. Cell Chem Biol. 2023, 30(5):553-568.e7.
6. Chang Y, Li X, Zhou Y, Yang X, Zhao W*, Fang H*, Hou X*. Simultaneous inhibition of FLT3 and HDAC by novel 6-ethylpyrazine-2-Carboxamide derivatives provides therapeutic advantages in acute myelocytic leukemia. Eur J Med Chem. 2024, 279:116847.
7. Liang X, Zhao H, Du J, Li X, Li K, Zhao Z, Bi W, Zhang X, Yu D, Zhang J, Fang H*, Hou X*. Discovery of benzofuran-2-carboxylic acid derivatives as lymphoid tyrosine phosphatase (LYP) inhibitors for cancer immunotherapy. Eur J Med Chem. 2023, 258:115599.
8. Liang T, Wang F, Elhassan RM, Cheng Y, Tang X, Chen W*, Fang H*, Hou X*. Targeting histone deacetylases for cancer therapy: Trends and challenges. Acta Pharm Sin B. 2023, 13(6):2425-2463.
9. Zhao Z, Du J, Du Y, Gao Y, Yu M, Zhang Y*, Fang H*, Hou X*. Deciphering the Allosteric Activation Mechanism of SIRT6 Using Molecular Dynamics Simulations. J Chem Inf Model. 2023, 63(18):5896-5902.
10. Elhassan RM, Hou X*, Fang H*. Recent advances in the development of allosteric protein tyrosine phosphatase inhibitors for drug discovery. Med. Res. Rev. 2022, 42(3):1064-1110.
11. Liu M, Gao S, Elhassan RM, Hou X*, Fang H*. Strategies to overcome drug resistance using SHP2 inhibitors. Acta Pharm. Sin. B. 2021,11(12):3908-3924.
12. Hou X, et al. Inhibition of striatal-enriched protein tyrosine phosphatase by targeting computationally revealed cryptic pockets, Eur. J. Med. Chem., 2020, 190:112131.
13. Liu L, Liu R, Yang X, Hou X*, Fang H*. Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors. Eur. J. Med. Chem., 2020, 191:112142.
14. Chen C, Yang X, Fang H*, Hou X*. Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors. Eur. J. Med. Chem. 2019, 181:111563.
15. Li K#, Hou X#, Li R#, Bi W#, Yang F, Chen X, Xiao P, Liu T, Lu T, Zhou Y, Tian Z, Shen Y, Zhang Y, Wang J, Fang H, Sun J*, Yu X.* Identification and structure-function analyses of an allosteric inhibitor of the tyrosine phosphatase PTPN22. J. Biol. Chem. 2019, 294(21):8653-8663.
16. Hou X, Rooklin D, Yang D, Liang X, Li K, Lu J, Wang C, Xiao P, Zhang Y, Sun JP, Fang H. Computational Strategy for Bound State Structure Prediction in Structure-Based Virtual Screening: A Case Study of Protein Tyrosine Phosphatase Receptor Type O Inhibitors. J. Chem. Inf. Model. 2018, 58(11):2331-2342.
17. Hou X, et al. Resveratrol serves as a protein-substrate interaction stabilizer in human SIRT1 activation. Sci. Rep., 2016, 6, 38186.
18. Hou X, et al. Protein Flexibility in Docking-Based Virtual Screening: Discovery of Novel Lymphoid-Specific Tyrosine Phosphatase Inhibitors Using Multiple Crystal Structures. J. Chem. Inf. Model. 2015, 55(9):1973-1983.
19. Hou X, et al. Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8. J. Chem. Inf. Model. 2015, 55(4):861-871.
20. Hou X, et al. Fast Identification of Novel Lymphoid Tyrosine Phosphatase Inhibitors Using Target-Ligand Interaction-Based Virtual Screening. J. Med. Chem. 2014, 57, 9309-9322.
获奖情况
全国高校教师教学创新大赛 二等奖(药物设计学,3/4)
山东省高校教师教学创新大赛 一等奖(药物设计学,3/4)
全国药学专业学位精品课程(药学信息学,3/3)
山东省研究生教育优质课程(药物信息学,3/3)
山东大学青年教师讲课比赛二等奖(药物设计学)
山东大学青年教学能手
全国药物化学学术会议优秀墙报奖
山东省研究生优秀科技创新成果奖
山东省优秀共青团员
“挑战杯”全国大学生课外学术科技作品竞赛二等奖
中国专利年会“校园发明与创新”金奖
学术兼职情况
Frontiers in Chemistry -Associate Editor, 《中国药物化学杂志》青年编委。
J. Med. Chem., Eur. J. Med. Chem., Theranostics, Bioorg. Chem., Phys. Chem. Chem. Phys.等杂志审稿人。
中国药学会高级会员, 中国化学会会员。
联系方式:
Email: hxb#sdu.edu.cn (#替换为@)
通讯地址:山东省济南市文化西路44号山东大学趵突泉校区
山东省济南市兴仲路国家大学科技园3#